Tag: Atopic Dermatitis
Upadacitinib: Fast and more pronounced skin improvement in AD patients
Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD
Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal
JAK inhibitors: A risk assessment
Monitoring is key during JAK inhibitor therapy
Ceramides and their role in skincare
Targeting OX40 in the treatment of atopic dermatitis meets expectations
Superior EASI scores after switch from dupilumab to upadacitinib
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis
AD patients with stable response fare well with a monthly dose of tralokinumab
Upadacitinib beats dupilumab in different body regions
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab
Ruxolitinib cream: a safe treatment for elderly AD patients
Novel and upcoming targeted AD treatment
Opioid receptor agonist difelikefalin disappoints in AD
EADV 2021 Highlights Podcast
Meaningful sleep improvement with IL-13 inhibition
Baricitinib in AD: Efficacy paired with consistent long-term results
Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD
Effects IL-13 blocker improves with longer treatment duration
Baricitinib beneficial in head and neck AD
Cannabinoids: a future role in dermatology?
Good response and pruritus reduction in AD with novel selective JAK1 inhibitor
IL-13 blocker tralokinumab effective in AD
Tape stripping – a painless way to distinguish AD and psoriasis?
IL-4/IL-13 blocker dupilumab effective in children with severe AD
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
JAK inhibition plus TCS lead to high clearance rates in AD
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Comorbidities more common in chronic urticaria, psoriasis, and AD
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Insights into pathogenesis of AD define novel therapeutic targets
Long awaited oral therapy for moderate-to-severe AD
Combinations are hot in AD treatment
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Atopic dermatitis and psoriasis: on a spectrum?
Bermekimab – a future treatment for atopic dermatitis?
New and emerging atopic dermatitis therapies
Can JAK inhibitors close the current therapeutic gap in AD?
Food triggers eczema – an imperturbable belief of patients
AD sleep disturbance, antihistamines and osteoporosis
IL-17C inhibition in AD and new oral treatments
New topical and systematic treatments
Dual JAK/SYK inhibitor and anti-IL-33 blockade
IL-4/IL-13 inhibition
